Clinical Trial Update: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating Interferon-Beta-1a (FP-1201) to prevent toxicities after CD19-directed CAR T-cell therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Interferon-Beta-1a (FP-1201) (Interferon beta-1a)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN